A Spanish study showed for the first time that more severe hepatic damage is evident in patients with both psoriasis and non-alcoholic fatty liver disease (NAFLD) .
Over the past 10 years, it has become increasingly evident that NAFLD is a multisystemic disease that affects extra-hepatic organ systems and interacts with the regulation of several metabolic and immunological pathways . The prevalence of NAFLD (diagnosed by imaging or by histology) is remarkably higher in psoriatic patients, occurring in up to 50% of patients . Of note, this association is evident even after adjusting for metabolic syndrome traits or other potential confounders. Up to now, no reports on a possible link between the severity of both conditions have been published.
To explore a possible association, a total of 64 male patients were included in a prospective 12-month study. Inclusion criteria were NAFLD (histologic steatosis >5%, sonographic steatosis >48 dB/m, no other hepatic conditions, and less than 30 g/d of alcohol intake) and severe psoriasis. Patients enrolled in the trial had a considerable comorbidity: their mean body mass index was 30.9 kg/m2, 53.1% had diabetes mellitus, and 42.2% suffered from hypertension. The Psoriasis Area and Severity Index score was used to measure the severity of psoriasis, while ultrasound elastography was used to judge the severity of NAFLD.
Results showed that psoriatic patients with NAFLD had indeed more severe elastographic hepatic damage if they had a higher level of psoriasis severity. “In this context, increasing awareness and the continued assessment of the severity of NAFLD in patients with psoriasis by primary care physicians, specialists, health policymakers, and patients should be prioritised to help manage both conditions,” said lead researcher Dr Daniel Nieto (La Paz Hospital, Spain).
- Nieto D, et al. Poster No 169, EADV 2019, 9-13 Oct, Madrid, Spain.
- Mantovani A, et al. Int J Mol Sci 2016;17:217.
« Novel selective IL-23 blocker equally effective in patients with metabolic syndrome Next Article
D-Dimer as future biomarker in CSU management? »
Table of Contents: EADV 2019
Letter from the Editor
IL-17A blocker effective in paediatric psoriasis patients
Rituximab beats mycophenolate mofetil in pemphigus vulgaris
Novel JAK1/2 inhibitor shows remarkable efficacy in alopecia areata
Acne highly influenced by climate, pollutants, and unhealthy diet
JAK inhibition plus TCS lead to high clearance rates in AD
No cancer risk with long-term use of tacrolimus, a topical calcineurin inhibitor, in children with AD
Green light for a second JAK inhibitor in AD
Topical ruxolitinib effective in vitiligo
Small molecules: interesting novel treatment options in AD
IL-1⍺ blockade: a new treatment option in AD
IL-4/IL-13 blockade leads to rapid itch reduction in adolescents
How to manage conjunctivitis in AD patients treated with a biologic
Biologics: increasingly used in paediatric dermatology
Spotlight on Psoriasis
IL-17 blocker: effective and safe in patients with comorbidities
ESPRIT registry: sharp decline in mortality in patients treated with a TNF blocker
Relationship psoriasis and NAFLD: new data on the hepato-dermal axis
Novel selective IL-23 blocker equally effective in patients with metabolic syndrome
Selective IL-23 blocker crushes fumaric acids in all assessed efficacy endpoints
No hint of teratogenicity through ixekizumab
New Insights in Photoprotection
Systemic photoprotection: a valuable addition to topical sun protection
The underestimated effect of visible light
Comorbidities more common in chronic urticaria, psoriasis, and AD
D-Dimer as future biomarker in CSU management?
Ligelizumab for CSU: symptom control and high response rates in re-treatment
Rosacea – From New Spectrum to New Therapy
New guidance on rosacea therapy according to phenotype
Best of the Posters
Above-the-neck melanoma more prone to metastases
Reduced sleep quality in dermatoses influenced by itch and pain
Anxiety and depression are common in families of AD infants
Certolizumab pegol efficacious for head and neck psoriasis
PFGC 2021 Highlights Podcast
Live varicella-zoster vaccine safe, effective with TNF inhibitors